As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of bioAffinity Technologies, Inc. The largest reported stake is Bigger Michael's, at 5.79%. One filing is on record since October 1, 2025 (Schedule 13G, October 1, 2025).
Sell to companies like bioAffinity Technologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Bigger Capital Fund L P · Sole voting: 0 · Shared voting: 58,682 · Sole dispositive: 0 · Shared dispositive: 58,682 · SCHEDULE 13G, 2025-10-01
- · Reporting person: Bigger Capital Fund GP, LLC · Sole voting: 0 · Shared voting: 58,682 · Sole dispositive: 0 · Shared dispositive: 58,682 · SCHEDULE 13G, 2025-10-01
- · Reporting person: District 2 Capital Fund LP · Sole voting: 0 · Shared voting: 58,682 · Sole dispositive: 0 · Shared dispositive: 58,682 · SCHEDULE 13G, 2025-10-01
- · Reporting person: District 2 Capital LP · Sole voting: 0 · Shared voting: 58,682 · Sole dispositive: 0 · Shared dispositive: 58,682 · SCHEDULE 13G, 2025-10-01
- · Reporting person: District 2 GP LLC · Sole voting: 0 · Shared voting: 58,682 · Sole dispositive: 0 · Shared dispositive: 58,682 · SCHEDULE 13G, 2025-10-01
bioAffinity Technologies, Inc. has 1 Schedule 13D or 13G filing on record since 2025-10-01. 1 holder's latest filing reports 5% or more of common stock, $0.007 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 5.79% | 117,364 | SCHEDULE 13G, 2025-10-01 | 2025-09-29 |
Holding shares or following this stake? See who's behind bioAffinity Technologies, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on bioAffinity Technologies, Inc. and the records around it.
bioAffinity Technologies, Inc. elsewhere on the record
- IPO filing Jun 2026
- Who owns it
Companies that share a holder
- BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies: ClearPoint Neuro, Inc. (Nov 2026), Dermata Therapeutics, Inc. (Nov 2026), BTC Digital Ltd. (Oct 2026)
Watch bioAffinity Technologies, Inc.
Get an email when bioAffinity Technologies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on bioAffinity Technologies, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on bioAffinity Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on bioAffinity Technologies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Bigger Capital Fund L P | 0 | 58,682 | 0 | 58,682 | SCHEDULE 13G, 2025-10-01 |
| Bigger Capital Fund GP, LLC | 0 | 58,682 | 0 | 58,682 | SCHEDULE 13G, 2025-10-01 |
| District 2 Capital Fund LP | 0 | 58,682 | 0 | 58,682 | SCHEDULE 13G, 2025-10-01 |
| District 2 Capital LP | 0 | 58,682 | 0 | 58,682 | SCHEDULE 13G, 2025-10-01 |
| District 2 GP LLC | 0 | 58,682 | 0 | 58,682 | SCHEDULE 13G, 2025-10-01 |
| District 2 Holdings LLC | 0 | 58,682 | 0 | 58,682 | SCHEDULE 13G, 2025-10-01 |
| Bigger Michael | 0 | 117,364 | 0 | 117,364 | SCHEDULE 13G, 2025-10-01 |
The latest filing names bioAffinity Technologies, Inc., with its principal executive office as 3300 NACOGDOCHES ROAD, SUITE 216, SAN ANTONIO, TX 78217 (SCHEDULE 13G, 2025-10-01).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-01 | Bigger Michael | 5.79% | SCHEDULE 13G |
Also on the record for bioAffinity Technologies, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 18, 2026 | IPO filing, Form 424B4 | $0.8 a share | IPO filings | Source |
| June 16, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| June 12, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| April 30, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| September 30, 2025 | IPO filing, Form 424B4 | — | IPO filings | Source |
| September 25, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| September 24, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| September 15, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| August 29, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| May 7, 2025 | IPO filing, Form 424B4 | — | IPO filings | Source |
| May 5, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| May 2, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
The newest 12 of 15 records.
Tools for this story
Each opens in a new tab, filled in for bioAffinity Technologies, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.